CBD and Diabetes: What the Science Shows.

Driven by obesity, diet, sedentariness, and aging, type 2 diabetes (T2D) continues to rise, with projections suggesting cases could double by 2050. In the U.S., ~38 million adults (≈12%) were living with T2D in 2024, and diabetes markedly elevates risks for cardiovascular disease, cancer, neurodegeneration, kidney disease, and neuropathy—substantially diminishing quality of life.^1–6

Treatment challenges. Pharmacotherapies carry GI effects, weight change, hypoglycemia, infection risk, and cost/complexity burdens; even with adherence, disease biology may progress and many complications persist. Comorbidities further complicate care.^7–13 Lifestyle change (nutrition, activity, weight loss) is highly effective—including a 58% risk reduction among people with impaired glucose tolerance and superiority to metformin in some prevention settings—yet difficult to sustain and resource-intensive to coach.^14–22

Amid integrative strategies to reduce risk and improve outcomes, cannabidiol (CBD) is drawing interest. Early evidence suggests anti-inflammatory, antioxidant, vascular, and metabolic actions relevant to diabetes pathophysiology and complications.^23–28

How CBD Intersects with Diabetes Biology

CBD engages the endocannabinoid system and other targets (e.g., TRP channels, 5-HT1A, PPAR-γ), influencing pathways implicated in insulin resistance, oxidative stress, vascular dysfunction, and neuroinflammation. Preclinical and small clinical studies indicate potential to modulate glucose regulation, protect vasculature and nerves, and affect symptom burden and quality of life.^23–28

Diabetes Support: How CBD May Help

1) Anti-inflammatory & Antioxidant Activity

Chronic low-grade inflammation contributes to insulin resistance and β-cell dysfunction. CBD has been shown to inhibit pro-inflammatory cytokines and NF-κB signaling, preserve hepatic/pancreatic tissues, and protect endothelial integrity under hyperglycemic/inflammatory stress. Its antioxidant effects mitigate ROS-driven microvascular and macrovascular injury—central to diabetes complications.^29–33

2) Insulin Sensitivity & Glucose Metabolism

Preclinical and pilot human data suggest CBD can influence hormones/receptors relevant to glycemic control. In one randomized pilot, CBD shifted resistin (↓) and glucose-dependent insulinotropic peptide (↑), hinting at improved glycemic profiles. CBD also interfaces with the gut microbiome—linked bidirectionally to metabolic disease—with studies indicating CBD can shape microbial composition toward taxa associated with healthier glucose/insulin dynamics. Signals from animal models and small trials include better insulin sensitivity and reduced glucose levels.^34–41

3) Neuropathy & Retinopathy

Neuropathic pain is common and difficult to treat. CBD demonstrates anti-inflammatory, antioxidant, and analgesic properties; it can reduce microglial activation and p38-MAPK phosphorylation, engage 5-HT1A and α3-glycine receptors, and has shown benefit in inflammatory/neuropathic pain models. In a small human study, topical CBD reduced neuropathic pain and pruritus versus placebo. Mechanistically, CBD’s vascular and neuroprotective effects support its promise in diabetic retinopathy as well.^42–48

4) Cardiovascular Disease & Cardiomyopathy

Up to a third of patients with T2D develop macrovascular disease. CBD shows vasorelaxant, endothelial-protective, and anti-proliferative effects (e.g., reduced hyperpermeability, inhibition of VSMC proliferation). Human crossover data show acute BP reductions under stress; animal and cellular studies suggest protection against ischemia-reperfusion injury and diabetic cardiomyopathy via reduced oxidative stress, inflammation, arrhythmogenesis, and sodium-channel dysfunction.^49–56

5) Stress, Anxiety & Sleep

Stress and sleep disruption worsen glycemic control by elevating cortisol, impairing insulin sensitivity, and derailing metabolic hormones. CBD’s anxiolytic effects are documented in human studies, and it has been associated with improved sleep latency, duration, and quality—factors that can indirectly support glucose regulation and complication risk.^57–65

Bottom Line

CBD’s multi-target mechanisms align with major drivers of T2D onset and complications: inflammation, oxidative stress, vascular and neural injury, and stress-sleep dysregulation. While larger, well-controlled trials are needed to define dose, formulation, and long-term outcomes, current evidence supports exploring CBD as a complementary adjunct alongside guideline-directed lifestyle and pharmacologic therapy—particularly where pain, sleep, anxiety, neuropathy, or vascular dysfunction are prominent.

References

CDC. National Diabetes Statistics Report. 2024.
Khan MAB et al. J Epidemiol Glob Health. 2020;10:107–111.
Siddiqui K et al. Front Endocrinol. 2022;13:1079725.
Dal Canto E et al. Eur J Prev Cardiol. 2019;26:25–32.
Gallagher EJ, LeRoith D. Physiol Rev. 2015;95:727–748.
Cholerton B et al. Diabetes Spectr. 2016;29:210–219.
Borse SP et al. Med Princ Pract. 2021;30:109–121.
Galindo RJ et al. BMJ Med. 2023;2:e000372.
Schroeder EB. In: Endotext. 2022.
Owens DR et al. Diabetes Obes Metab. 2017;19:1339–1352.
Aloke C et al. Biomedicines. 2022;10:2436.
Gieroba B et al. Biochem Biophys Rep. 2025;42:102037.
Nikpour S et al. Interact J Med Res. 2022;11:e41933.
Galaviz KI et al. Am J Lifestyle Med. 2018;12:4–20.
Knowler WC et al. NEJM. 2002;346:393–403.
Ingul CB et al. Diabetes Res Clin Pract. 2025;220:111998.
Wang B et al. World J Diabetes. 2020;11:261–268.
de Hoogh IM et al. Nutrients. 2021;13:2193.
Katula JA et al. Contemp Clin Trials. 2017;53:89–99.
Franceschi R. J Pers Med. 2022;12:1233.
Fuller H, Alberti H. Br J Gen Pract. 2017;67:61.
Gupta L et al. Eur Endocrinol. 2019;15:18–24.
Blaschke F et al. ATVB. 2006;26:28–40.
Zhang J et al. Exploration (Beijing). 2023;3:20230047.
Mattes RG et al. Diabetes Spectr. 2021;34:198–201.
Jyotsna F et al. Cureus. 2023;15:e43882.
Britch SC et al. Psychopharmacology. 2021;238:9–28.
Crippa JA et al. Front Immunol. 2018;9:2009.
Hammell DC et al. Eur J Pain. 2016;20:936–948.
Horváth B et al. Am J Pathol. 2012;180:432–442.
Giacco F, Brownlee M. Circ Res. 2010;107:1058–1070.
Fine PG, Rosenfeld MJ. Rambam Maimonides Med J. 2013;4:e0022.
Kumar RN et al. Anaesthesia. 2001;56:1059–1068.
Jadoon KA et al. Diabetes Care. 2016;39:1777–1786.
Bielawiec P et al. Front Endocrinol. 2020;11:114.
Thu MS et al. Biomed Pharmacother. 2025;182:117764.
Wu J et al. Protein Cell. 2021;12:360–373.
Cani PD et al. Nat Rev Endocrinol. 2016;12:133–143.
Muccioli GG et al. Mol Syst Biol. 2010;6:392.
Cani PD et al. Nat Rev Gastroenterol Hepatol. 2022;19:625–637.
Zhuang X et al. J Gastroenterol Hepatol. 2017;32:28–38.
Toth CC et al. Mol Pain. 2010;6:16.
Jesus CHA et al. Brain Res. 2019;1715:156–164.
Xiong W et al. J Exp Med. 2012;209:1121–1134.
Costa B et al. Eur J Pharmacol. 2007;556:75–83.
Xu DH et al. Curr Pharm Biotechnol. 2020;21:390–402.
Liou GI. World J Diabetes. 2010;1:12–18.
Liou G et al. Curr Pharmacogenomics Person Med. 2009;7:215–222.
Stanley CP et al. Br J Clin Pharmacol. 2013;75:313–322.
Resstel LB et al. Br J Pharmacol. 2009;156:181–188.
Jadoon KA et al. JCI Insight. 2017;2:e93760.
Dillmann WH. Circ Res. 2019;124:1160–1162.
Rajesh M et al. JACC. 2010;56:2115–2125.
Fouda MA et al. Br J Pharmacol. 2020;177:2932–2946.
Fouda MA, Ruben PC. Front Pharmacol. 2021;12:668657.
Grisanti LA. Front Physiol. 2018;9:1669.
Sharma K et al. Cureus. 2022;14:e29142.
Nedeltcheva AV, Scheer FA. Curr Opin Endocrinol Diabetes Obes. 2014;21:293–298.
Barone MT, Menna-Barreto L. Diabetes Res Clin Pract. 2011;91:129–137.
Grandner MA et al. Curr Diab Rep. 2016;16:106.
Blessing EM et al. Neurotherapeutics. 2015;12:825–836.
Wright M et al. Cannabis Cannabinoid Res. 2020;5:191–196.
Shannon S et al. Perm J. 2019;23:18-041.
Bergamaschi MM et al. Neuropsychopharmacology. 2011;36:1219–1226.
Henson JD et al. J Clin Med. 2021;10:5852.